Dr. Reddy’s Laboratories (NYSE:RDY) Shares Gap Down – Should You Sell?

Dr. Reddy’s Laboratories Limited (NYSE:RDY)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $13.71, but opened at $13.41. Dr. Reddy’s Laboratories shares last traded at $13.44, with a volume of 87,686 shares.

Analyst Ratings Changes

A number of research analysts recently issued reports on RDY shares. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Down 1.3 %

The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The company has a market cap of $11.08 billion, a price-to-earnings ratio of 21.14 and a beta of 0.48. The firm has a 50 day moving average price of $13.55 and a two-hundred day moving average price of $14.64.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, equities analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Institutional Trading of Dr. Reddy’s Laboratories

A number of institutional investors have recently bought and sold shares of RDY. Robeco Institutional Asset Management B.V. boosted its position in shares of Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Dr. Reddy’s Laboratories by 609.4% during the 4th quarter. Van ECK Associates Corp now owns 5,838 shares of the company’s stock worth $92,000 after buying an additional 5,015 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Dr. Reddy’s Laboratories by 400.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock worth $8,373,000 after buying an additional 427,573 shares during the period. World Investment Advisors LLC bought a new stake in shares of Dr. Reddy’s Laboratories in the 3rd quarter valued at $3,459,000. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Dr. Reddy’s Laboratories by 328.3% during the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company’s stock valued at $201,000 after acquiring an additional 9,781 shares during the period. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.